Bolar Exemption

The Bolar exemption is the patent safe harbor provision in 35 U.S.C. § 271(e)(1), created to enable generic drug competition: THE PRE-BOLAR PROBLEM: before Hatch-Waxman (1984), generic drug manufacturers could not conduct FDA bioequivalence testing using a patented drug compound while the patent was still in force; any use of the patented compound — even for testing — constituted infringement; the result: generic manufacturers could not BEGIN the FDA approval process until the patent expired; FDA review itself takes 1-4 years; the combination effectively extended the brand's market exclusivity well beyond the patent term; THE ROCHE PRODUCTS v. BOLAR PHARMACEUTICALS CASE (Fed. Cir. 1984): Bolar Pharmaceutical used patented flurazepam (Roche's Dalmane) for bioequivalence testing before the patent expired; the Federal Circuit ruled that Bolar's testing DID constitute patent infringement; there was no common law experimental use exception for commercial purposes; the court acknowledged the result created a de facto patent extension; CONGRESSIONAL RESPONSE: Congress immediately enacted the Hatch-Waxman Act (1984) including § 271(e)(1) to overrule Roche v. Bolar: 'It shall not be an act of infringement to make, use, offer to sell, or sell within the United States or import into the United States a patented invention...solely for uses reasonably related to the development and submission of information under a Federal law which regulates the manufacture, use, or sale of drugs'; BALANCE: Hatch-Waxman balanced the Bolar exemption (enabling generic testing) with patent term restoration (§ 156) compensating brand-name pharmaceutical companies for FDA-caused delays; the balance was intended to ensure innovation incentives while promoting generic competition.

The Bolar exemption has a specific scope that has been refined by major court decisions: ACTIVITIES COVERED: bioequivalence studies (clinical and in vitro); clinical trials for generic ANDA or biosimilar BLA submissions; preclinical (animal) testing for FDA submissions (Merck v. Integra, 2005); pharmacokinetic and pharmacodynamic studies; stability testing for regulatory submissions; formulation development research related to regulatory submissions; ANDA AND BIOSIMILAR APPLICATIONS: generic manufacturers can use any patented drug compound in ANDA (Abbreviated New Drug Application) preparation; biosimilar manufacturers can conduct interchangeability studies under the safe harbor; MEDICAL DEVICES AND OTHER FDA-REGULATED PRODUCTS: Eli Lilly v. Medtronic (S.Ct. 1990): the exemption covers medical devices regulated by the Medical Device Amendments; the 'Federal law' that regulates includes all FDA-regulated products (drugs, devices, biologics, animal drugs, food); ACTIVITIES NOT COVERED: commercial manufacturing beyond FDA submission needs; stockpiling products for post-patent commercial launch; activities with no reasonable connection to an FDA submission; purely academic research using patented compounds as tools; activities in foreign countries for foreign regulatory submissions (§ 271(e)(1) applies to activities 'within the United States'); manufacturing for export for foreign regulatory submissions is not clearly covered; THE 'SOLELY' REQUIREMENT: the activity must be SOLELY related to FDA submission; if an activity serves both regulatory AND commercial purposes, it may not be fully exempt; courts look at the totality of the activity's purpose; companies should document the regulatory purpose of all activities relying on the exemption.

The Bolar exemption is embedded in the Hatch-Waxman framework that governs generic drug patent challenges: HATCH-WAXMAN ANDA PROCESS: a generic manufacturer files an ANDA (Abbreviated New Drug Application) with the FDA; the ANDA references the brand's NDA (New Drug Application) and must certify that the generic is bioequivalent; PARAGRAPH IV CERTIFICATION: when patents are listed in the FDA's Orange Book (the Approved Drug Products with Therapeutic Equivalence Evaluations), the generic must certify regarding each listed patent; PARAGRAPH IV: the listed patent is invalid, unenforceable, or will not be infringed by the generic product; filing a Paragraph IV certification is deemed an act of infringement (35 U.S.C. § 271(e)(2)) — a legal fiction that allows the patent holder to sue; 45-DAY WINDOW AND 30-MONTH STAY: if the patent holder sues within 45 days of receiving the Para IV notice, the FDA is automatically stayed from approving the generic for 30 months; during the 30-month stay: the Bolar exemption allows the generic to continue FDA submission preparation and testing; the generic may not commercially manufacture or stockpile; FIRST FILER 180-DAY EXCLUSIVITY: the first generic company to file a Para IV ANDA receives 180 days of market exclusivity upon FDA approval; this incentivizes generic companies to challenge patents early; during litigation, the first filer can use the Bolar exemption to prepare for launch; AT-RISK LAUNCHES: a generic company may obtain FDA approval and launch commercially before the patent litigation resolves; if the patent is later found valid and infringed, the generic owes the brand lost profits or reasonable royalty; this is a major financial risk; BIOSIMILAR BPCIA: the Biologics Price Competition and Innovation Act (BPCIA) creates a similar but more complex framework for biosimilars; 12-year data exclusivity for reference biologics; biosimilar patent dance involves extensive patent disclosure before litigation.

Most countries have enacted Bolar-style exemptions, but the scope varies significantly: EUROPE: European Patent Convention (EPC) does not itself include a Bolar exemption; individual EU member states have enacted their own; DIRECTIVE 2004/27/EC (EU) on medicinal products required member states to allow generic manufacturers to conduct tests for MA (marketing authorization) applications; most EU countries have implemented broad Bolar exemptions covering not just generics but also other regulatory activities; UK: Patents Act 1977, Section 60(5)(d): acts done for experimental purposes are exempt; for regulatory submissions: broadly exempt under UK national Bolar provision; CANADA: Regulatory activities exemption under the Patent Act; covers activities for Health Canada submissions; Supreme Court of Canada has considered scope; JAPAN: experimental and research exemption in Patent Act Article 69; pharmaceutical research for regulatory submissions generally exempt; INDIA: Section 107A of the Patents Act (India Bolar): 'making, constructing, using, selling or importing a patented invention solely for uses reasonably related to the development and submission of information required...to a regulatory authority in India or in a country other than India'; notably: India's Bolar exemption explicitly covers activities for FOREIGN regulatory submissions — broader than the US exemption; AUSTRALIA: Patents Act 1990, Section 119A: regulatory activities for TGA (Therapeutic Goods Administration) submissions are exempt; TRIPS ARTICLE 30: permits limited exceptions that do not unreasonably conflict with normal exploitation and do not unreasonably prejudice legitimate interests; Bolar exemptions are generally considered TRIPS-compliant under Article 30; SCOPE COMPARISON: India's Bolar is among the broadest (covers foreign submissions); US is limited to US FDA submissions; European scope varies by country but generally broad.

Brand-name drug companies and medical device makers challenge Bolar exemption claims in several ways: CHALLENGE 1 — ACTIVITIES NOT SOLELY RELATED TO FDA SUBMISSIONS: argue the generic's activities go beyond what is reasonably related to FDA submission preparation; if the generic is manufacturing product in excess of bioequivalence study needs, it is stockpiling; stockpiling is not exempt (Intermedics v. Guidant, Fed. Cir. 2001); CHALLENGE 2 — RESEARCH TOOL ARGUMENT: argue the patented technology is used as a general research tool rather than as the subject of FDA submissions; if the patented compound is a research reagent used in screening assays, not the compound being submitted for approval, the exemption may not apply; CHALLENGE 3 — NON-FDA REGULATORY ACTIVITIES: argue the activities relate to foreign (non-FDA) regulatory submissions; § 271(e)(1) applies to US FDA submissions; manufacturing in the US for EMA or PMDA submissions is not clearly covered; CHALLENGE 4 — SCOPE OF COVERED PATENTS: argue the specific patent claims cover something beyond what the safe harbor protects; for example, a method-of-use patent may claim a specific medical indication; if the generic is testing for a different indication than the patented claim, the exemption may not apply to the patented claim; REVERSE PAYMENTS (PAY-FOR-DELAY): brand companies sometimes pay generic companies to delay their Para IV challenge launch; FTC v. Actavis (S.Ct. 2013): such 'reverse payment' settlements are subject to antitrust rule of reason scrutiny; they do not violate antitrust per se, but large reverse payments can be anticompetitive; PEDIATRIC EXCLUSIVITY: brands can obtain 6-month pediatric exclusivity by conducting pediatric clinical trials, delaying generic entry; pediatric testing itself may use patented compounds under the Bolar exemption.